Quest Diagnostics launches opioid therapy genetic test

Monday, August 12, 2013

Quest Diagnostics, a provider of diagnostic information services, has launched a lab-developed genetic test to aid the delivery of personalized opioid pain-relieving treatment. It is the first clinical lab to offer testing for variants in all cytochrome P450 (CYP450) genes known to influence the CYP450 enzyme system, which affects metabolism of opioids and other medications.

[Read More]